Ozieranski P[au] - Search Results

Year	Number of Results
2011	1
2012	2
2013	1
2014	4
2016	4
2018	3
2019	11
2020	3
2021	8
2022	5

1

Exposing drug industry funding of UK patient organisations.

Ozieranski P, Rickard E, Mulinari S. Ozieranski P, et al. BMJ. 2019 May 22;365:l1806. doi: 10.1136/bmj.l1806. BMJ. 2019. PMID: 31122928 Free PMC article.

2

The Emerging Social Science Literature on Health Technology Assessment: A Narrative Review.

Löblová O, Trayanov T, Csanádi M, Ozierański P. Löblová O, et al. Among authors: ozieranski p. Value Health. 2020 Jan;23(1):3-9. doi: 10.1016/j.jval.2019.07.016. Epub 2019 Sep 16. Value Health. 2020. PMID: 31952670 Free article. Review.

3

Drug company payments to General Practices in England: Cross-sectional and social network analysis.

Saghy E, Mulinari S, Ozieranski P. Saghy E, et al. Among authors: ozieranski p. PLoS One. 2021 Dec 7;16(12):e0261077. doi: 10.1371/journal.pone.0261077. eCollection 2021. PLoS One. 2021. PMID: 34874975 Free PMC article.

4

The whistleblowing drama behind Astellas's suspension from the ABPI.

Cohen D, Mulinari S, Ozieranski P. Cohen D, et al. Among authors: ozieranski p. BMJ. 2019 Jul 2;366:l4353. doi: 10.1136/bmj.l4353. BMJ. 2019. PMID: 31266743 No abstract available.

5

A hidden web of policy influence: The pharmaceutical industry's engagement with UK's All-Party Parliamentary Groups.

Rickard E, Ozieranski P. Rickard E, et al. Among authors: ozieranski p. PLoS One. 2021 Jun 24;16(6):e0252551. doi: 10.1371/journal.pone.0252551. eCollection 2021. PLoS One. 2021. PMID: 34166396 Free PMC article.

6

Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review.

Ozieranski P, Martinon L, Jachiet PA, Mulinari S. Ozieranski P, et al. BMJ Open. 2021 Dec 16;11(12):e053138. doi: 10.1136/bmjopen-2021-053138. BMJ Open. 2021. PMID: 34916317 Free PMC article. Review.

7

Divergent spender: State-societal and meso-organisational mechanisms in the containment of public spending on pharmaceuticals in a liberal capitalist democracy.

Main B, Ozieranski P. Main B, et al. Among authors: ozieranski p. Sociol Health Illn. 2021 Jul;43(6):1518-1539. doi: 10.1111/1467-9566.13343. Epub 2021 Jul 15. Sociol Health Illn. 2021. PMID: 34263470

8

Is there evidence for the racialization of pharmaceutical regulation? Systematic comparison of new drugs approved over five years in the USA and the EU.

Mulinari S, Vilhelmsson A, Ozieranski P, Bredström A. Mulinari S, et al. Among authors: ozieranski p. Soc Sci Med. 2021 Jul;280:114049. doi: 10.1016/j.socscimed.2021.114049. Epub 2021 May 20. Soc Sci Med. 2021. PMID: 34044186 Free article.

9

Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries.

Mulinari S, Martinon L, Jachiet PA, Ozieranski P. Mulinari S, et al. Among authors: ozieranski p. Health Policy. 2021 Jul;125(7):915-922. doi: 10.1016/j.healthpol.2021.04.015. Epub 2021 May 4. Health Policy. 2021. PMID: 34006392 Free article.

10

Shedding light on the HTA consultancy market: Insights from Poland.

Csanádi M, Ozierański P, Löblová O, King L, Kaló Z, Botz L. Csanádi M, et al. Among authors: ozieranski p. Health Policy. 2019 Dec;123(12):1237-1243. doi: 10.1016/j.healthpol.2019.08.008. Epub 2019 Aug 20. Health Policy. 2019. PMID: 31466804

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results